PMID: 7538044Jun 1, 1995Paper

The role of tumor rejection antigens in host antitumor defense mechanisms

Cancer
F A CampbellD Bouchier-Hayes

Abstract

Normal cells undergo contact inhibition of growth when their surface molecules interact. Tumor cells, however, have undergone a mutation that prevents this arrest of growth upon contact inhibition and allows constant growth. Thus, growth inhibition fails to occur despite the interaction of surface molecules. In recent years a subgroup of these surface molecules has been of interest to cancer investigators. This subgroup has been termed the tumor rejection antigens (TRAs). As the name implies, these are specific to the tumor of origin and may direct the immune system of the host to target the tumor cells and kill them. A literature search was carried out on TRAs to ascertain the current thinking on the subject. Initial studies of TRAs have revealed that some of them may be heat shock proteins (HSPs). In particular, grp96, a number of the HSP90 family, has been implicated. More recent studies, however, have shown that HSPs alone may not be immunogenic but may act as carrier proteins for tumor specific peptides. Such findings have led to speculation that HSPs or their associated peptides may have a role in the diagnosis and/or treatment of specific cancers. Immunotherapy and bispecific antibodies in particular are areas in which H...Continue Reading

References

Jan 1, 1992·Cancer Treatment and Research·J B Breitmeyer
Sep 1, 1992·Cancer·J D Beatty
Jul 9, 1992·Nature·H WiechU Jakob
Jan 1, 1991·Current Topics in Microbiology and Immunology·P K Srivastava, R G Maki
Jan 24, 1991·Nature·G Winter, C Milstein
Apr 1, 1990·British Journal of Cancer·A Cook, J Milner
Apr 1, 1990·Immunology Today·S H Kaufmann
Aug 16, 1990·Biochemical and Biophysical Research Communications·Y NumataI Yamashina
Oct 27, 1989·Science·T TakahashiJ D Minna
Jun 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·A F LoBuglioM B Khazaeli
Aug 1, 1986·Experimental Cell Research·M TavassoliK Harjes
Jun 1, 1987·The American Journal of Physiology·B S PollaS M Krane
Mar 24, 1988·Nature·L RiechmannG Winter
May 1, 1988·Immunology Today·B S Polla
Aug 24, 1987·Journal of Immunological Methods·S L TopalianS A Rosenberg
May 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·S J UllrichE Appella
May 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·P K SrivastavaL J Old
Jun 1, 1987·Experimental Cell Research·N I MoldovanN Simionescu
Jan 1, 1987·International Journal of Radiation Applications and Instrumentation. Part B, Nuclear Medicine and Biology·D ColcherJ Schlom
Jan 15, 1987·International Journal of Cancer. Journal International Du Cancer·J M EstebanJ Schlom
Jan 1, 1985·Critical Reviews in Oncology/hematology·J E Shively, J D Beatty
Apr 15, 1974·Journal of Molecular Biology·A TissièresU M Tracy
Apr 1, 1984·Proceedings of the National Academy of Sciences of the United States of America·D G Lowe, L A Moran
Oct 1, 1982·Proceedings of the National Academy of Sciences of the United States of America·W E MercerR Baserga

❮ Previous
Next ❯

Citations

Jul 11, 2001·Biochemical and Biophysical Research Communications·C H LeungW F Fong
Jun 20, 2007·Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association·M Salih Deveci, Güzin Deveci
Jul 18, 1997·Brain Research. Developmental Brain Research·D Parnas, M Linial
Sep 3, 2009·Molecular Therapy : the Journal of the American Society of Gene Therapy·Makiya NishikawaYoshinobu Takakura
Jun 14, 2006·Journal of Pediatric Surgery·Yi YangChang Lin Wang
Aug 1, 1996·Hematology/oncology Clinics of North America·D Y Kavanaugh, D P Carbone

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody Engineering

Antibody engineering technologies are constantly advancing to improve the clinical effectiveness of monoclonal and bispecific antibodies. Discover the latest research on Antibody Engineering here.